Search - tctmd.com

Displaying 61 - 80 of 211

Sort: Relevancy | Date

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

November 2023 News Roundup

News Opinion CV Team Dispatch

November 2023 News Roundup

November 01, 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

October 2023 News Roundup

News Opinion CV Team Dispatch

October 2023 News Roundup

October 01, 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

News Daily News

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

June 16, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

TCTMD’s Top 10 Most Popular Stories for April 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2023

April 28, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

March 14, 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

March 10, 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.